CRISPR Therapeutics CRSP Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's proceeds from exercises of stock options and other stock issuances?
- CRISPR Therapeutics (CRSP) reported proceeds from exercises of stock options and other stock issuances of $6.16M in Q1 2026.
- How has CRISPR Therapeutics's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- CRISPR Therapeutics's proceeds from exercises of stock options and other stock issuances increased by 197.2% year-over-year, from $2.07M to $6.16M.
- What is the long-term trend for CRISPR Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's proceeds from exercises of stock options and other stock issuances has grown at a -7.2% compound annual growth rate (CAGR), from $37.68M to $27.94M.